home icon

right icon

Stocks

right icon

WINDLAS

WINDLAS

WINDLAS

Pharmaceuticals & Drugs

263.25

0.00 (0.00%)

stock change
Market Cap569 CrEPS21.1High264.8
Stock P/E12.5Net Profit Margin9.2Low259.35
home icon
The current prices are delayed, login to your account to see live prices.
LOGIN
explain

Performance

Today’s Low

Today’s High

259.35

264.8

52W Low

52W High

203.25

295.45

Open Price259.35Volume1
Prev. Close261.95
explain

Fundamentals

explain
Market Cap569 CrROE12.9%
P/E Ratio(TTM)12.5EPS(TTM)18.9
P/B Ratio1.4Dividend Yield1.3%
Industry P/E65.5Book Value188.9
Face Value5.0
explain

About the Company

Windlas Biotech is amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (CDMO) industry in India in terms of revenue. With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances and low solubility, it provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (GMP) with a focus on improved safety, efficacy and cost. In addition to providing services and products in the CDMO market, it also sell its own branded products in the trade generics and OTC markets as well as export generic products to several countries.

The company’s CDMO Services and Products SBV is focused on providing products and services across a diverse range of pharmaceutical and nutraceutical generic products for Indian and multinational pharmaceutical companies who market such products under their own brand names to the end users. The company’s Domestic Trade Generics and OTC Brands SBV consists of (i) trade generic products; and (ii) OTC brands, which include nutraceutical and health supplement products that do not require prescription and are marketed, distributed and promoted in India under its own brand names through online and offline channels and majorly manufactured by it. Trade generic products are generic medicines, i.e. drugs for which the patents have expired, which are sold directly to the distributor and not marketed through medical representatives, and are typically used as a substitute for more expensive branded generic medicines in order to offer affordable medicines to patients by the retailers and pharmacies. The company’s Exports SBV is engaged in identifying high growth markets and opportunities in semi-regulated international markets as well as selected regulated markets, for developing and registering product applications to obtain marketing authorizations for generic medicines and health supplements and subsequently, sell such products to pharmaceutical companies and pharmacies in the respective markets.

Business area of the company

The company provides pharmaceutical development services, large-scale manufacturing services and authentic yet affordable products to its customers and consumers around the world.

Awards, accreditations and recognitions

  • 2018: The company was awarded the TV100 Industrial Excellence Award in the field of medicine.
  • 2019: The company was awarded the certificate of appreciation from the Secretary, Bureau of Energy Efficiency for valuable contributions in implementing energy efficiency and cleaner production measures under the project ‘Financing Energy Efficiency at MSMEs’.
  • 2019: The company was awarded the certificate of partnership recognizing its contribution to and participation in the Swasth Bharat Yatra, a pan-India cyclothon organised by the Food Safety and Standards Authority of India.

Major events and milestones

  • 2001: Commenced operations at Dehradun Plant - I situated at 40/1, Mohabewala Industrial Area, Dehradun 248 110 and initiated commercial production.
  • 2009: Commenced operations at Dehradun Plant - IV situated at plot no. 183 and 192, Mohabewala Industrial Area, Dehradun 248 110.
  • 2010: Revenues crossed Rs 1,000 million for the FY 2009-10.
  • 2014: Received first USFDA inspection clearance for the WHC Plant.
  • 2014: Revenues crossed Rs 2,000 million for the FY 2013-14.
  • 2014: Commenced operations at Dehradun Plant - II situated at khasra no. 141 to 143 and 145, Mohabewala Industrial Area, Dehradun 248 110.
  • 2015: Investment of Rs 750 million from Tano India Private Equity Fund II.
  • 2017: Revenues crossed Rs 3,000 million for the FY 2016-17.
  • 2018: Launched first product in the United States from the Dehradun Plant - IV situated at plot no. 183 and 192, Mohabewala Industrial Area, Dehradun.
  • 2018: Commenced operations at Dehradun Plant - III situated at plot no. 39, Pharmacity, Selaqui, Dehradun.
  • 2021: Approval of Scheme of Amalgamation of its erstwhile subsidiary, Windlas Healthcare, with and into the company.
Parent OrganisationWindlas Biotech Ltd.Managing DirectorHitesh Windlass
Founded2001NSE SymbolWINDLAS
explain

Financials

All values are in Rs Cr

explain

Shareholding Pattern

explain

Peer Comparison

Company52 WeekMarket PriceP/E Ratio
SEE MORE
explain

Recently Viewed

No Recently Viewed Stocks
explain

Frequently asked questions

You can buy the shares of Windlas Biotech using the Trinkerr Website or by downloading the Trinkerr app from Android and Apptore.